Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-randomized, Single-dose, Open-Label, Pharmacokinetic Study of Cebranopadol in Patients With Impaired Renal Function and Subjects With Normal Renal Function

NCT03882762 is registered in ClinicalTrials.gov with Tris Pharma, Inc. as lead sponsor.

NCT NCT03882762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03882762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-randomized, Single-dose, Open-Label, Pharmacokinetic Study of Cebranopadol in Patients With Impaired Renal Function and Subjects With Normal Renal Function
Lead sponsor
Tris Pharma, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 20, 2013
Completion date
September 17, 2014
Enrollment
34 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pharmacokinetic